Shattuck Labs (NASDAQ:STTK) Insider Sells $14,244.32 in Stock

Posted by Francis Steltz on May 14th, 2026

Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report) insider Abhinav Shukla sold 2,032 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $7.01, for a total transaction of $14,244.32. Following the completion of the transaction, the insider owned 81,258 shares of the company’s stock, valued at approximately $569,618.58. This trade represents a 2.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shattuck Labs Stock Down 1.2%

Shares of NASDAQ:STTK traded down $0.08 during trading on Thursday, reaching $6.67. 413,393 shares of the company’s stock traded hands, compared to its average volume of 547,218. Shattuck Labs, Inc. has a fifty-two week low of $0.71 and a fifty-two week high of $8.33. The company has a 50-day simple moving average of $6.61 and a 200-day simple moving average of $4.46. The firm has a market cap of $511.46 million, a PE ratio of -10.59 and a beta of 1.18.

Shattuck Labs (NASDAQ:STTK – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. During the same period last year, the firm posted ($0.27) earnings per share. On average, equities research analysts forecast that Shattuck Labs, Inc. will post -0.51 EPS for the current year.

Institutional Investors Weigh In On Shattuck Labs

Large investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its holdings in shares of Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Shattuck Labs during the first quarter worth approximately $81,000. Acadian Asset Management LLC boosted its stake in Shattuck Labs by 27.6% during the first quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock worth $243,000 after buying an additional 55,687 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Shattuck Labs in the 2nd quarter valued at $44,000. Finally, Jane Street Group LLC grew its holdings in Shattuck Labs by 2,510.8% in the 2nd quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock valued at $229,000 after buying an additional 278,576 shares in the last quarter. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on STTK. Citigroup increased their target price on Shattuck Labs from $4.00 to $7.00 and gave the company a “neutral” rating in a research report on Friday, March 13th. TD Cowen reiterated a “buy” rating on shares of Shattuck Labs in a research report on Friday, March 6th. HC Wainwright boosted their target price on shares of Shattuck Labs from $6.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Finally, Wedbush raised their price target on shares of Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Get Our Latest Report on STTK

About Shattuck Labs

(Get Free Report)

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.